Lixte Biotechnology Files S-1/A Amendment

TL;DR

LIXT filed an S-1/A amendment, looks like they're prepping for a stock offering.

AI Summary

Lixte Biotechnology Holdings, Inc. filed an S-1/A amendment on November 1, 2024, to its registration statement. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry and is headquartered in East Setauket, NY. This filing is an amendment to a previous registration statement filed under the Securities Act of 1933.

Why It Matters

This S-1/A filing indicates Lixte Biotechnology is moving forward with its plans to register securities, which could lead to future fundraising or public offerings. Investors should monitor this for potential stock changes.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can introduce volatility and risk for investors.

Key Numbers

• 333-282781 — SEC File Number (Identifies this specific registration filing with the SEC.)
• 202903526 — IRS Number (Employer Identification Number for Lixte Biotechnology Holdings, Inc.)

Key Players & Entities

• LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
• November 1, 2024 (date) — Filing Date
• 333-282781 (registration_number) — SEC File Number
• Bastiaan van der Baan (person) — Chief Executive Officer
• David L. Ficksman, Esq. (person) — Legal Counsel

FAQ

Key Financial Figures

• $0.0001 — of one share of common stock, par value $0.0001 per share (“common stock”)
• $2.11 — at an assumed public offering price of $2.11 per Unit, which was the closing price o
• $4,000,000 — r gross proceeds of up to approximately $4,000,000. Each Common Warrant offered hereby is
• $0 — luding one share of common stock, minus $0.001, and the exercise price of each Pre
• $0.001 — e of each Pre-Funded Warrant will equal $0.001 per share. The Pre-Funded Warrants will
• $75,000 — ding its legal fees, up to a maximum of $75,000. See “Plan of Distribution”

Filing Documents

• forms-1a.htm (S-1/A) — 543KB
• ex4-5.htm (EX-4.5) — 122KB
• ex4-6.htm (EX-4.6) — 116KB
• ex4-7.htm (EX-4.7) — 120KB
• ex5-1.htm (EX-5.1) — 19KB
• ex10-23.htm (EX-10.23) — 65KB
• ex10-24.htm (EX-10.24) — 290KB
• ex23-1.htm (EX-23.1) — 4KB
• forms-1_001.jpg (GRAPHIC) — 74KB
• forms-1_002.jpg (GRAPHIC) — 685KB
• forms-1_003.jpg (GRAPHIC) — 139KB
• forms-1_004.jpg (GRAPHIC) — 384KB
• ex5-1_001.jpg (GRAPHIC) — 20KB
• ex5-1_002.jpg (GRAPHIC) — 10KB
• 0001493152-24-043388.txt ( ) — 3086KB

RISK FACTORS

RISK FACTORS 18 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 23

USE OF PROCEEDS

USE OF PROCEEDS 26 CAPITALIZATION 27

DILUTION

DILUTION 28 SELECTED HISTORICAL FINANCIAL DATA 30

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 31 PLAN OF DISTRIBUTION 35 LEGAL MATTERS 38 EXPERTS 38 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 39 WHERE YOU CAN FIND MORE INFORMATION 39 4 ABOUT THIS PROSPECTUS You should rely only on the information contained in or incorporated by reference into this prospectus and in any free writing prospectus. We have not and the placement agent has not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of our securities. Neither we nor the placement agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside of the United States. We own or have rights to trademarks or trade names that we use in connection with the operation of our business, including our corporate names, logos and website names. In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that protect the content of our products. This prospectus may also contain trademarks, service marks and trade names of other companies, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this prospectus is not intended t

View Full Filing

View this S-1/A filing on SEC EDGAR